Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Anders

Showing results (191-200 of 247) with videos related to

Pageof 25
Sort By:
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Cancer|August 12, 2003
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaCaroline Laverdiere, E Anders Kolb, Jeffrey G Supko, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Oncotarget|June 15, 2018
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profilingKatherine Tarlock, Shan Zhong, Yuting He, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Cancer Research|August 7, 2016
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse AnalysisBrendan Murphy, Han Yin, John M Maris, et al.
Pageof 25

Showing results (191-200 of 247) with videos related to

Sort By:
Pageof 25
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Cancer|August 12, 2003
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaCaroline Laverdiere, E Anders Kolb, Jeffrey G Supko, et al.
Pediatric Blood & Cancer|July 12, 2011
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Molecular Cancer Therapeutics|January 8, 2010
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Oncotarget|June 15, 2018
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profilingKatherine Tarlock, Shan Zhong, Yuting He, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Cancer Research|August 7, 2016
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse AnalysisBrendan Murphy, Han Yin, John M Maris, et al.
Pageof 25